Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
; 106(2): 543-554, 2021 02 01.
Article
in En
| MEDLINE
| ID: mdl-32107341
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Lymphocytic, Chronic, B-Cell
Type of study:
Clinical_trials
/
Guideline
Limits:
Humans
Language:
En
Journal:
Haematologica
Year:
2021
Type:
Article
Affiliation country:
Germany